Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 31c
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.25), $0.31 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $126.17 million versus the consensus estimate of $119.72 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Pulmatrix (PULM) Reports Q2 Loss of $0.29
- Benchmark Reiterates Buy Rating on Jumia Technologies (JMIA)
Create E-mail Alert Related Categories
EarningsRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
